These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
728 related articles for article (PubMed ID: 28138040)
1. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040 [TBL] [Abstract][Full Text] [Related]
2. In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu Witkin JM; Ornstein PL; Mitch CH; Li R; Smith SC; Heinz BA; Wang XS; Xiang C; Carter JH; Anderson WH; Li X; Broad LM; Pasqui F; Fitzjohn SM; Sanger HE; Smith JL; Catlow J; Swanson S; Monn JA Neuropharmacology; 2017 Mar; 115():100-114. PubMed ID: 26748052 [TBL] [Abstract][Full Text] [Related]
3. Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity. Chappell MD; Li R; Smith SC; Dressman BA; Tromiczak EG; Tripp AE; Blanco MJ; Vetman T; Quimby SJ; Matt J; Britton TC; Fivush AM; Schkeryantz JM; Mayhugh D; Erickson JA; Bures MG; Jaramillo C; Carpintero M; Diego JE; Barberis M; Garcia-Cerrada S; Soriano JF; Antonysamy S; Atwell S; MacEwan I; Condon B; Sougias C; Wang J; Zhang A; Conners K; Groshong C; Wasserman SR; Koss JW; Witkin JM; Li X; Overshiner C; Wafford KA; Seidel W; Wang XS; Heinz BA; Swanson S; Catlow JT; Bedwell DW; Monn JA; Mitch CH; Ornstein PL J Med Chem; 2016 Dec; 59(24):10974-10993. PubMed ID: 28002967 [TBL] [Abstract][Full Text] [Related]
4. Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects. Witkin JM; Monn JA; Li J; Johnson B; McKinzie DL; Wang XS; Heinz BA; Li R; Ornstein PL; Smith SC; Mitch CH; Calligaro DO; Swanson S; Allen D; Phillips K; Gilmour G Pharmacol Biochem Behav; 2017 Apr; 155():43-55. PubMed ID: 28285123 [TBL] [Abstract][Full Text] [Related]
5. mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects. Witkin JM Pharmacol Biochem Behav; 2020 Mar; 190():172854. PubMed ID: 31954773 [TBL] [Abstract][Full Text] [Related]
6. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960 [TBL] [Abstract][Full Text] [Related]
7. The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice. Pałucha-Poniewiera A; Podkowa K; Rafało-Ulińska A Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110239. PubMed ID: 33400944 [TBL] [Abstract][Full Text] [Related]
8. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Koike H; Chaki S Behav Brain Res; 2014 Sep; 271():111-5. PubMed ID: 24909673 [TBL] [Abstract][Full Text] [Related]
9. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Fukumoto K; Iijima M; Chaki S Psychopharmacology (Berl); 2014 Jun; 231(11):2291-8. PubMed ID: 24402133 [TBL] [Abstract][Full Text] [Related]
10. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant]. Chaki S Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Aug; 32(4):219-26. PubMed ID: 23012890 [TBL] [Abstract][Full Text] [Related]
11. Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. Podkowa K; Pochwat B; Brański P; Pilc A; Pałucha-Poniewiera A Psychopharmacology (Berl); 2016 Aug; 233(15-16):2901-14. PubMed ID: 27286960 [TBL] [Abstract][Full Text] [Related]
12. mGlu2/3 receptor as a novel target for rapid acting antidepressants. Chaki S Adv Pharmacol; 2020; 89():289-309. PubMed ID: 32616210 [TBL] [Abstract][Full Text] [Related]
13. Modulation by chronic stress and ketamine of ionotropic AMPA/NMDA and metabotropic glutamate receptors in the rat hippocampus. Elhussiny MEA; Carini G; Mingardi J; Tornese P; Sala N; Bono F; Fiorentini C; La Via L; Popoli M; Musazzi L; Barbon A Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110033. PubMed ID: 32640261 [TBL] [Abstract][Full Text] [Related]
14. Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment. O' Connor RM; Pusceddu MM; Dinan TG; Cryan JF Neuropharmacology; 2013 Mar; 66():236-41. PubMed ID: 22609536 [TBL] [Abstract][Full Text] [Related]
16. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Ago Y; Yano K; Araki R; Hiramatsu N; Kita Y; Kawasaki T; Onoe H; Chaki S; Nakazato A; Hashimoto H; Baba A; Takuma K; Matsuda T Neuropharmacology; 2013 Feb; 65():29-38. PubMed ID: 23022081 [TBL] [Abstract][Full Text] [Related]
17. On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Pałucha-Poniewiera A; Wierońska JM; Brański P; Stachowicz K; Chaki S; Pilc A Psychopharmacology (Berl); 2010 Dec; 212(4):523-35. PubMed ID: 20703449 [TBL] [Abstract][Full Text] [Related]
18. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Lorrain DS; Schaffhauser H; Campbell UC; Baccei CS; Correa LD; Rowe B; Rodriguez DE; Anderson JJ; Varney MA; Pinkerton AB; Vernier JM; Bristow LJ Neuropsychopharmacology; 2003 Sep; 28(9):1622-32. PubMed ID: 12825094 [TBL] [Abstract][Full Text] [Related]
19. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Koike H; Iijima M; Chaki S Neuropharmacology; 2011 Dec; 61(8):1419-23. PubMed ID: 21903115 [TBL] [Abstract][Full Text] [Related]
20. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Koike H; Fukumoto K; Iijima M; Chaki S Behav Brain Res; 2013 Feb; 238():48-52. PubMed ID: 23098797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]